Revolution Medicines, Inc. (RVMD)
NasdaqGS · USD · Healthcare · Biotechnology
$183.90 (-1.65%) as of
Key statistics
- Market cap
- 39.42B
- Forward P/E
- -31.91
- EPS (TTM)
- -8.71
- Dividend yield
- 0.00%
- 52-week range
- 55.40 – 224.31
- Beta
- 1.40
- Profit margin
- 0.00%
- Analyst target
- $258.84
- Volume
- 1.66M
About Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Redwood City, CA, United States
- Employees
- 883
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.